South San Francisco, Calif. — November 18, 2025 — Leads & Copy — BridgeBio Oncology Therapeutics, Inc. (BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, announced today that members of its leadership team will participate in two investor conferences in December.
The first presentation will be at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, at 2:00 p.m. ET. The second presentation will be at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, at 9:35 a.m. ET.
Live webcasts of the presentations will be accessible on the “Events” page of the BBOT website at https://investors.bbotx.com/news-events/events. Replays of the webcasts will be available for at least 90 days following the event.
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
Investor Contact:
Heather Armstrong
BBOT
Heather.Armstrong@bbotx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
Source: BridgeBio Oncology Therapeutics, Inc.
Source: BridgeBio Oncology Therapeutics, Inc.
